Neoadjuvant Chemotherapy in Breast Cancer: Evaluation of the Impact on Surgical Outcomes and Prognosis
Authors:
- Corrado ChiappaCCCorrado Chiappa
- Maltecca GretaMGMaltecca Greta
- Leoni MiriamLMLeoni Miriam
- Giuseppe IettoGiuseppe Ietto
- Davide InversiniDIDavide Inversini
- Andrea BallabioABAndrea Ballabio
- Alice BonettiABAlice Bonetti
- Alberto ManganoAlberto Mangano
- Rossana GueliRGRossana Gueli
- Giulio CarcanoGCGiulio Carcano
- Francesca Angela RoveraFRFrancesca Angela Rovera
Open Access
Abstract
The correlation between TNM staging and histology variations in a sample of patients who underwent neoadjuvant chemotherapy demonstrates a positive impact on both increasing conservative surgery and achieving pCR, resulting in better outcomes in terms of disease-free survival (DFS) and the risk of relapse. Benefits have also been highlighted in terms of cosmetic outcomes, postoperative complications, and psychological benefits. However, the overall outcomes must be evaluated according to the subtype and individual characteristics of the patients.Keywords
This publication has 28 references indexed in Scilit:
- Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast CancerJAMA Surgery, 2023
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast CancerJAMA Surgery, 2020
- NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapyContemporary Clinical Trials Communications, 2020
- Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastasesBreast Cancer Research and Treatment, 2017
- Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United StatesCancer, 2015
- Neoadjuvant Therapy in the Treatment of Breast CancerSurgical Oncology Clinics of North America, 2014
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryBreast Cancer Research and Treatment, 2013
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapyEuropean Journal of Cancer, 2012
- Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancerBreast Cancer Research and Treatment, 2012